Skip to main content
    K

    Kalaris Therapeutics, Inc. (KLRS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.43
    -0.03 (-2.05%)

    Market Cap: $34.76M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Kalaris Therapeutics, Inc. (KLRS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Kalaris Therapeutics (KLRS) has a market cap of $34.76M. Its share count is up 27.29% from a year earlier. It holds $47.38M more cash than debt, 136.34% of its market cap.

    Total Valuation

    Market Cap$34.76M
    Latest price (Nov 17, 2026)$1.43

    Key Dates

    The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 15, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.03% in the quarter ended Sep 30, 2026 and grew 319.57% a year over 2 years.

    Shares Outstanding23.80M
    Shares Change (YoY)+27.29%
    Shares Change (QoQ)+0.03%
    Share Count Growth (2Y CAGR)+319.57%

    Price Statistics

    The stock is down 73.81% over 52 weeks and trades 41.63% below its 50-day average.

    Beta (1Y)0.55
    52-Week Change-73.81%
    1-Month Change-25.13%
    3-Month Change-65.71%
    6-Month Change-69.57%
    5-Year Change-99.63%
    Total Return (1Y)-73.81%
    Total Return (3Y CAGR)-66.33%
    Total Return (5Y CAGR)-68.86%
    Return vs SPY (1Y)-89.39%
    Max Drawdown (1Y)-86.98%
    Max Drawdown (3Y)-97.40%
    Sharpe Ratio (1Y)-1.77
    Correlation with SPY (1Y)0.09
    50-Day Average$2.45
    200-Day Average$4.95
    52-Week Range$1.41 to $11.88
    RSI (14 Days)29.0
    Average Volume (20 Days)86.86K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 10.00x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio10.00x
    Quick Ratio10.00x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -91.55% and return on assets is -48.76% over the last 12 months.

    Return on Equity (ROE)-91.55%
    Return on Assets (ROA)-48.76%
    Return on Capital Employed (ROCE)-53.91%
    ROIC (5Y Average)-43.51%

    Scores

    KLRS has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Gross Profit-$10.00K
    Operating Income-$46.83M
    Pretax Income-$43.40M
    Net Income-$43.40M
    EBIT-$43.40M
    Reported EPS (TTM)-$1.84

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 53.26% of the $89.00M in total assets.

    Cash and Equivalents$47.38M
    Total Debt$0
    Net Cash$47.38M
    Net Cash Per Share$1.99
    Working Capital$76.66M
    Shareholder Equity$47.40M
    Book Value Per Share$1.99
    Total Assets$89.00M
    Total Liabilities$41.60M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$40.24M
    FCF Per Share-$1.69
    Depreciation and Amortization$745.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-65.80%
    Tangible Book Per Share Growth (2Y CAGR)-65.80%

    Revenue and profit by year

    Stock Splits

    The last split was a 1-for-23 reverse split on Jan 16, 2025.

    Last Split DateJan 16, 2025
    Split TypeReverse split
    Split Ratio1:23

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About KLRS

    What is KLRS's market cap?

    Kalaris Therapeutics has a market cap of $34.76M.

    How many shares of KLRS are outstanding?

    Kalaris Therapeutics has 23.80M shares outstanding. The count is up 27.29% from a year earlier.

    Does KLRS pay a dividend?

    No. Kalaris Therapeutics does not pay a dividend.

    How much debt does KLRS have?

    Kalaris Therapeutics has $0 of total debt and $47.38M of cash and equivalents, a net cash position of $47.38M.